Identification of Critical Paraoxonase 1 Residues Involved in High Density Lipoprotein Interaction

被引:23
作者
Gu, Xiaodong [1 ]
Huang, Ying [1 ]
Levison, Bruce S. [1 ]
Gerstenecker, Gary [3 ]
DiDonato, Anthony J. [1 ]
Hazen, Leah B. [1 ]
Lee, Joonsue [1 ]
Gogonea, Valentin [1 ,3 ]
DiDonato, Joseph A. [1 ]
Hazen, Stanley L. [1 ,2 ]
机构
[1] Cleveland Clin, Ctr Cardiovasc Diagnost & Prevent, Dept Cellular & Mol Med, Cleveland, OH 44195 USA
[2] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44195 USA
[3] Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA
基金
美国国家卫生研究院;
关键词
CORONARY-HEART-DISEASE; APOLIPOPROTEIN-A-I; SERUM PARAOXONASE; LIPID-PEROXIDATION; CHOLESTEROL EFFLUX; PROTEOMIC ANALYSIS; LACTONASE ACTIVITY; PROTEIN; MYELOPEROXIDASE; HDL;
D O I
10.1074/jbc.M115.678334
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Paraoxonase 1 (PON1) is a high density lipoprotein (HDL)-associated protein with atherosclerosis-protective and systemic anti-oxidant functions. We recently showed that PON1, myeloperoxidase, and HDL bind to one another in vivo forming a functional ternary complex (Huang, Y., Wu, Z., Riwanto, M., Gao, S., Levison, B. S., Gu, X., Fu, X., Wagner, M. A., Besler, C., Gerstenecker, G., Zhang, R., Li, X. M., Didonato, A. J., Gogonea, V., Tang, W. H., et al. (2013) J. Clin. Invest. 123, 3815-3828). However, specific residues onPON1 involved in the HDL-PON1 interaction remain unclear. Unambiguous identification of protein residues involved in docking interactions to lipid surfaces poses considerable methodological challenges. Here we describe a new strategy that uses a novel synthetic photoactivatable and click chemistry-taggable phospholipid probe, which, when incorporated into HDL, was used to identify amino acid residues on PON1 that directly interact with the lipoprotein phospholipid surface. Several specific PON1 residues (Leu-9, Tyr-185, and Tyr-293) were identified through covalent crosslinks with the lipid probes using affinity isolation coupled to liquid chromatography with on-line tandem mass spectrometry. Based upon the crystal structure for PON1, the identified residues are all localized in relatively close proximity on the surface of PON1, defining a domain that binds to the HDL lipid surface. Site-specific mutagenesis of the identified PON1 residues (Leu-9, Tyr-185, and Tyr-293), coupled with functional studies, reveals their importance in PON1 binding to HDL and both PON1 catalytic activity and stability. Specifically, the residues identified on PON1 provide important structural insights into the PON1-HDL interaction. More generally, the new photoactivatable and affinity-tagged lipid probe developed herein should prove to be a valuable tool for identifying contact sites supporting protein interactions with lipid interfaces such as found on cell membranes or lipoproteins.
引用
收藏
页码:1890 / 1904
页数:15
相关论文
共 87 条
[71]   Clinical and Genetic Association of Serum Paraoxonase and Arylesterase Activities With Cardiovascular Risk [J].
Tang, W. H. Wilson ;
Hartiala, Jaana ;
Fan, Yiying ;
Wu, Yuping ;
Stewart, Alexandre F. R. ;
Erdmann, Jeanette ;
Kathiresan, Sekar ;
Roberts, Robert ;
McPherson, Ruth ;
Allayee, Hooman ;
Hazen, Stanley L. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2012, 32 (11) :2803-+
[72]   Diminished Antioxidant Activity of High-Density Lipoprotein-Associated Proteins in Systolic Heart Failure [J].
Tang, W. H. Wilson ;
Wu, Yuping ;
Mann, Shirley ;
Pepoy, Michael ;
Shrestha, Kevin ;
Borowski, Allen G. ;
Hazen, Stanley L. .
CIRCULATION-HEART FAILURE, 2011, 4 (01) :59-64
[73]   High-density lipoproteins: A consensus statement from the National Lipid Association [J].
Toth, Peter P. ;
Barter, Philip J. ;
Rosenson, Robert S. ;
Boden, William E. ;
Chapman, M. John ;
Cuchel, Marina ;
D'Agostino, Ralph B., Sr. ;
Davidson, Michael H. ;
Davidson, W. Sean ;
Heinecke, Jay W. ;
Karas, Richard H. ;
Kontush, Anatol ;
Krauss, Ronald M. ;
Miller, Michael ;
Rader, Daniel J. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2013, 7 (05) :484-525
[74]   Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice [J].
Tward, A ;
Xia, YR ;
Wang, XP ;
Shi, YS ;
Park, C ;
Castellani, LW ;
Lusis, AJ ;
Shih, DM .
CIRCULATION, 2002, 106 (04) :484-490
[75]   Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL [J].
Vaisar, Tomas ;
Pennathur, Subramaniam ;
Green, Pattie S. ;
Gharib, Sina A. ;
Hoofnagle, Andrew N. ;
Cheung, Marian C. ;
Byun, Jaeman ;
Vuletic, Simona ;
Kassim, Sean ;
Singh, Pragya ;
Chea, Helen ;
Knopp, Robert H. ;
Brunzell, John ;
Geary, Randolph ;
Chait, Alan ;
Zhao, Xue-Qiao ;
Elkon, Keith ;
Marcovina, Santica ;
Ridker, Paul ;
Oram, John F. ;
Heinecke, Jay W. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (03) :746-756
[76]   Crossroads in the evaluation of paraoxonase 1 for protection against nerve agent and organophosphate toxicity [J].
Valiyaveettil, Manojkumar ;
Alamneh, Yonas A. ;
Doctor, Bhupendra P. ;
Nambiar, Madhusoodana P. .
TOXICOLOGY LETTERS, 2012, 210 (01) :87-94
[77]   Thematic Review Series: High Density Lipoprotein Structure, Function, and Metabolism HDL and cholesterol: life after the divorce? [J].
Vickers, Kasey C. ;
Remaley, Alan T. .
JOURNAL OF LIPID RESEARCH, 2014, 55 (01) :4-12
[78]   MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins [J].
Vickers, Kasey C. ;
Palmisano, Brian T. ;
Shoucri, Bassem M. ;
Shamburek, Robert D. ;
Remaley, Alan T. .
NATURE CELL BIOLOGY, 2011, 13 (04) :423-U182
[79]   Protein carbamylation links inflammation, smoking, uremia and atherogenesis [J].
Wang, Zeneng ;
Nicholls, Stephen J. ;
Rodriguez, E. Rene ;
Kummu, Outi ;
Horkko, Sohvi ;
Barnard, John ;
Reynolds, Wanda F. ;
Topol, Eric J. ;
DiDonato, Joseph A. ;
Hazen, Stanley L. .
NATURE MEDICINE, 2007, 13 (10) :1176-1184
[80]   Protective effect of high density lipoprotein associated paraoxonase - Inhibition of the biological activity of minimally oxidized low density lipoprotein [J].
Watson, AD ;
Berliner, JA ;
Hama, SY ;
LaDu, BN ;
Faull, KF ;
Fogelman, AM ;
Navab, M .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (06) :2882-2891